Conatus Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Conatus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Conatus Pharmaceuticals: 16 sponsored US clinical trials, none currently recruiting.
Conatus Pharmaceuticals sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 0 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hepatic Cirrhosis, with 1 trials.
Top-decile sponsor footprint
Conatus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
16 total, page 1 of 1
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
NCT03479125
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
NCT02686762
A Study of IDN-6556 in Subjects With Liver Cirrhosis
NCT02230670
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
NCT02230683
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
NCT02138253
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
NCT02121860
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
NCT02077374
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
NCT02039817
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
NCT01937130
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
NCT01912404
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
NCT01273064
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
NCT01051921
CTS-1027 in Interferon-Naive Hepatitis C Patients
NCT00925990
Study of CTS-1027 in Hepatitis C Patients
NCT00570336
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
NCT00088140
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
NCT00080236
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 13 |
Therapeutic Areas
How the Conatus Pharmaceuticals early-phase archive is shaped
16 indexed studies, none listed as recruiting (0% open); 12 completed (75%).
Phase mix: 0 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Hepatic Cirrhosis (1 trial), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Conatus Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Conatus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 archived trials
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Conatus Pharmaceuticals page
16 registered trials is a research-attention snapshot, not an endorsement of Conatus Pharmaceuticals or any single study.
- None of Conatus Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hepatic Cirrhosis is the condition Conatus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatic Cirrhosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Conatus Pharmaceuticals pipeline card: 16 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.